Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 22147898
Zennadi R, et al. (2012) Erythrocyte plasma membrane-bound ERK1/2 activation promotes ICAM-4-mediated sickle red cell adhesion to endothelium. Blood 119, 1217-27 22147898
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S355-p - ADD1 (human)
Modsite: kYKAKsRsPGsPVGE SwissProt Entrez-Gene
Orthologous residues
ADD1 (human): S355‑p, ADD1 iso2 (human): S355‑p, ADD1 iso3 (human): S355‑p, ADD1 iso4 (human): S355‑p, ADD1 (mouse): S355‑p, ADD1 iso2 (mouse): S355‑p, ADD1 iso3 (mouse): S355‑p, ADD1 (rat): S355‑p, ADD1 (cow): A355‑p
Characterization
Methods used to characterize site in vivo western blotting
Relevant cell lines - cell types - tissues:  erythrocyte-blood
Cellular systems studied:  primary cells
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE ERK2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme, modification site within consensus motif, phospho-antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
U0126 decrease

S358-p - ADD1 (human)
Modsite: AKsRsPGsPVGEGtG SwissProt Entrez-Gene
Orthologous residues
ADD1 (human): S358‑p, ADD1 iso2 (human): S358‑p, ADD1 iso3 (human): S358‑p, ADD1 iso4 (human): S358‑p, ADD1 (mouse): T358‑p, ADD1 iso2 (mouse): T358‑p, ADD1 iso3 (mouse): T358‑p, ADD1 (rat): T358‑p, ADD1 (cow): S358‑p
Characterization
Methods used to characterize site in vivo western blotting
Relevant cell lines - cell types - tissues:  erythrocyte-blood
Cellular systems studied:  primary cells
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE ERK2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme, modification site within consensus motif, phospho-antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
U0126 decrease

S669-p - ADD1 (human)
Modsite: EEAHRPPsPtEAPTE SwissProt Entrez-Gene
Orthologous residues
ADD1 (human): S669‑p, ADD1 iso2 (human): , ADD1 iso3 (human): S700‑p, ADD1 iso4 (human): , ADD1 (mouse): D667‑p, ADD1 iso2 (mouse): , ADD1 iso3 (mouse): , ADD1 (rat): D667‑p, ADD1 (cow): S704‑p
Characterization
Methods used to characterize site in vivo western blotting
Relevant cell lines - cell types - tissues:  erythrocyte-blood
Cellular systems studied:  primary cells
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE ERK2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme, modification site within consensus motif, phospho-antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
U0126 decrease

S707-p - ADD1 (human)
Modsite: GAAADPGsDGsPGKs SwissProt Entrez-Gene
Orthologous residues
ADD1 (human): S707‑p, ADD1 iso2 (human): , ADD1 iso3 (human): S738‑p, ADD1 iso4 (human): , ADD1 (mouse): S705‑p, ADD1 iso2 (mouse): , ADD1 iso3 (mouse): , ADD1 (rat): S705‑p, ADD1 (cow): S739‑p
Characterization
Methods used to characterize site in vivo western blotting
Relevant cell lines - cell types - tissues:  erythrocyte-blood
Cellular systems studied:  primary cells
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE ERK2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme, modification site within consensus motif, phospho-antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
U0126 decrease

S592-p - ADD2 (human)
Modsite: tAPEEPGsPAksAPA SwissProt Entrez-Gene
Orthologous residues
ADD2 (human): S592‑p, ADD2 iso2 (human): , ADD2 (mouse): S594‑p, ADD2 iso2 (mouse): , ADD2 (rat): S594‑p, ADD2 iso2 (rat):
Characterization
Methods used to characterize site in vivo western blotting
Relevant cell lines - cell types - tissues:  erythrocyte-blood
Cellular systems studied:  primary cells
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE ERK2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme, modification site within consensus motif, phospho-antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
U0126 decrease

S596-p - ADD2 (human)
Modsite: EPGsPAksAPAsPVQ SwissProt Entrez-Gene
Orthologous residues
ADD2 (human): S596‑p, ADD2 iso2 (human): , ADD2 (mouse): S598‑p, ADD2 iso2 (mouse): , ADD2 (rat): S598‑p, ADD2 iso2 (rat):
Characterization
Methods used to characterize site in vivo western blotting
Relevant cell lines - cell types - tissues:  erythrocyte-blood
Cellular systems studied:  primary cells
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE ERK2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme, modification site within consensus motif, phospho-antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
U0126 decrease

S600-p - ADD2 (human)
Modsite: PAksAPAsPVQsPAK SwissProt Entrez-Gene
Orthologous residues
ADD2 (human): S600‑p, ADD2 iso2 (human): , ADD2 (mouse): S602‑p, ADD2 iso2 (mouse): , ADD2 (rat): S602‑p, ADD2 iso2 (rat):
Characterization
Methods used to characterize site in vivo western blotting
Relevant cell lines - cell types - tissues:  erythrocyte-blood
Cellular systems studied:  primary cells
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE ERK2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme, modification site within consensus motif, phospho-antibody

T307-p - CAP1 (human)
Modsite: FsAPKPQtsPsPkRA SwissProt Entrez-Gene
Orthologous residues
CAP1 (human): T307‑p, CAP1 iso2 (human): T306‑p, CAP1 (mouse): T306‑p, CAP1 (rat): T306‑p
Characterization
Methods used to characterize site in vivo western blotting
Relevant cell lines - cell types - tissues:  erythrocyte-blood
Cellular systems studied:  primary cells
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
racepinefrine decrease in Sickle cell RBCs

S310-p - CAP1 (human)
Modsite: PKPQtsPsPkRAtKk SwissProt Entrez-Gene
Orthologous residues
CAP1 (human): S310‑p, CAP1 iso2 (human): S309‑p, CAP1 (mouse): S309‑p, CAP1 (rat): S309‑p
Characterization
Methods used to characterize site in vivo western blotting
Relevant cell lines - cell types - tissues:  erythrocyte-blood
Cellular systems studied:  primary cells
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
racepinefrine decrease in Sickle cell RBCs
racepinefrine increase in AA RBCs

S90-p - dematin (human)
Modsite: ERsLSPKstsPPPsP SwissProt Entrez-Gene
Orthologous residues
dematin (human): S90‑p, dematin iso2 (human): S90‑p, dematin (mouse): S90‑p, dematin iso2 (mouse): S90‑p, dematin (rat): S90‑p
Characterization
Methods used to characterize site in vivo western blotting
Relevant cell lines - cell types - tissues:  erythrocyte-blood
Cellular systems studied:  primary cells
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE ERK2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme, modification site within consensus motif, phospho-antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
U0126 decrease

S96-p - dematin (human)
Modsite: KstsPPPsPEVWADs SwissProt Entrez-Gene
Orthologous residues
dematin (human): S96‑p, dematin iso2 (human): S96‑p, dematin (mouse): S96‑p, dematin iso2 (mouse): S96‑p, dematin (rat): S96‑p
Characterization
Methods used to characterize site in vivo western blotting
Relevant cell lines - cell types - tissues:  erythrocyte-blood
Cellular systems studied:  primary cells
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE ERK2 (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE ERK2 (human) pharmacological inhibitor of upstream enzyme, modification site within consensus motif, phospho-antibody
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
U0126 decrease

S540-p - EPB41 (human)
Modsite: RTASKRAsRsLDGAA SwissProt Entrez-Gene
Orthologous residues
EPB41 (human): S540‑p, EPB41 iso2 (human): S540‑p, EPB41 iso4 (human): S331‑p, EPB41 iso5 (human): S505‑p, EPB41 (mouse): S541‑p, EPB41 iso3 (mouse): , EPB41 iso6 (mouse): S264‑p, EPB41 (rat): S539‑p
Characterization
Methods used to characterize site in vivo western blotting
Relevant cell lines - cell types - tissues:  erythrocyte-blood
Cellular systems studied:  primary cells
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ERK2 (human) increase
U0126 ERK2 (human) inhibit treatment-induced increase in SS RBCs
U0126 ERK2 (human) no effect upon treatment-induced increase in AA RBCs

S542-p - EPB41 (human)
Modsite: ASKRAsRsLDGAAAV SwissProt Entrez-Gene
Orthologous residues
EPB41 (human): S542‑p, EPB41 iso2 (human): S542‑p, EPB41 iso4 (human): S333‑p, EPB41 iso5 (human): S507‑p, EPB41 (mouse): S543‑p, EPB41 iso3 (mouse): , EPB41 iso6 (mouse): S266‑p, EPB41 (rat): S541‑p
Characterization
Methods used to characterize site in vivo western blotting
Relevant cell lines - cell types - tissues:  erythrocyte-blood
Cellular systems studied:  primary cells
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
ERK2 (human) increase
U0126 ERK2 (human) inhibit treatment-induced increase in SS RBCs
U0126 ERK2 (human) no effect upon treatment-induced increase in AA RBCs